Table 1.
The suppression effects of transformed phenotypes following introduction of normal human chromosomes into various tumor cell types.
| Transferred Chromosome | Cell Lines | Type | Mapping Region | Reference | ||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||||
| 1 | HT1080 (fibrosarcoma) | + | + | [30] | ||||
| TE85(osteosarcoma) | + | [44] | ||||||
| 143 B (TK-Ki-Ras-transformed TE85) | + | [44] | ||||||
| CMV-Mj-HEL-1 (CMV-transfermed lung fibroblasts) | + | [44] | ||||||
| 10W-2 (immortal Syrian hamster fibroblasts) | + | [51] | ||||||
| Isikawa (uterine endomerial carcinoma) | + | * | ||||||
| HHUA (uterine endometrial carcinoma) | + | + | [45] | |||||
| 2 | SiHa (cervical cancer) | + | 2q37 | [31,32] | ||||
| 3 | RCC23 (renal cell carcinoma) | + | + | 3p21.3 | [40,46,54] | |||
| KC12 (renal cell carcinoma) | + | + | 3p14.2-p21.1 | [33] | ||||
| HSC3 (oral squamous cell carcinoma) | + | + | + | 3p21.2-p21.3 or 3p25 | [41,55] | |||
| TS1 (lung adenocarcinoma) | + | * | ||||||
| 4 | HeLa (cevical cancer) | + | [47] | |||||
| J82 (baladder cancer) | + | [47] | ||||||
| T98G (glioblastoma) | + | [47] | ||||||
| 5 | A2058 (melanoma) | + | + | [26,39] | ||||
| 6 | HALneo (immortal fibroblasts) | + | [48] | |||||
| LCS-AF.1-3 (immortal fibroblasts) | + | 6p23-p24 | [56] | |||||
| 39neo (immortal fibroblasts) | + | [48] | ||||||
| SV/HF (SV40-tranformed fibroblasts) | + | [48] | ||||||
| HPV-16 (HPV-immortalized keratinocyte) | + | [53] | ||||||
| 7 | KMST-6 (immortal fibroblasts) | + | [49] | |||||
| SUSM-1 (immortal fibroblasts) | + | [49] | ||||||
| CC1 (choriocarcinoma) | + | * | ||||||
| R-3327 (rat prostatic cancer cells) | + | 7q21-22, 7q31.2-32 | [57] | |||||
| MeT5A (mesothelial cells) | + | + | [52] | |||||
| 8 | R-3327 (rat prostatic cancer cells) | + | 8p21-q12 | [57] | ||||
| 10 | Li7HM (hepatocellular carcinoma) | + | + | 10p15.1 | [35] | |||
| R-3327 (rat prostatic cancer cells) | + | 10q11-22 | [57] | |||||
| 11 | HeLa (cevical cancer) | + | [58] | |||||
| G401 (wilm’s tumor) | + | + | [59] | |||||
| SiHa (cervical cancer) | + | [29] | ||||||
| A204 (rhadboyomyosarcoma) | + | [29] | ||||||
| HHUA (uterine endometrial carcinoma) | + | [29] | ||||||
| HT1080 (fibrosarcoma) | + | [30] | ||||||
| RD (rhabdomyosarcoma) | + | [50] | ||||||
| H15 (bladder cancer) | + | * | ||||||
| R-3327 (rat prostatic cancer cells) | + | 11p13-11.2 | [57] | |||||
| 13 | R-3327 (rat prostatic cancer cells) | + | [60] | |||||
| 17 | R-3327 (rat prostatic cancer cells) | + | 12p11-q13, 12q24-ter | [57] | ||||
| 18 | HHUA (uterine endometrial carcinoma) | + | + | [45] | ||||
| X | HocB (ovarian carcinoma) | + | * | |||||
| ELCO (breast carcinoma) | + | * | ||||||
Type 1: Induced senescence; Type 2: Suppression of in vitro transformed; Type 3: Suppression of tumorigenicity; Type 4: Suppression of telomerase activity; *: Unpublished data by the authors; +: Effective.